- eXmoor Pharma has partnered with Signadori Bio to advance gene-modified monocyte cell therapy targeting solid tumours.
- The agreement includes full technology translation, CMC planning, and GMP manufacturing readiness for first-in-human trials.

eXmoor Pharma, a UK-based CDMO with embedded consultancy capabilities, has announced a collaboration with France’s Signadori Bio to accelerate the development of gene-modified monocyte-derived macrophage therapies for solid tumours.
The partnership will focus on advancing Signadori Bio’s lead candidate—developed at the Gustave Roussy Institute—from early discovery through to GMP-compliant manufacturing. eXmoor Pharma will conduct technology translation and process development at its Cell & Gene Therapy Centre, and provide an interim Head of CMC to support Signadori’s internal team.
The agreement forms part of a structured programme aimed at guiding the therapy into first-in-human trials. The partners will work under a shared decision-making framework to align technical, scientific and commercial milestones with Signadori Bio’s investment strategy. The collaboration is expected to evolve into full GMP manufacturing activities.
Angela Osborne, CEO and Founder of eXmoor Pharma, said: “We are delighted to partner with Signadori Bio on such a promising and sophisticated cell therapy programme… This collaboration reflects our shared belief in the potential of advanced therapies to deliver meaningful outcomes for patients.”
Matthieu Coutet, CEO of Signadori Bio and Partner at Sofinnova Partners, added: “Partnering with eXmoor is a decisive step in our mission to bring next-generation monocyte-based therapies to patients with solid tumours… We’re excited to work hand-in-hand with a team that understands the complexity and urgency of advancing pioneering science into impactful therapies.”